PTK2 and non-small cell lung carcinoma: Our study reveals that FAK inhibition led to significant reduction in the expression of FRK in H358-S and NSCLC cells, whereas FRK expression remains unchanged upon dasatinib treatment suggesting that FRK might work downstream of FAK.